menu
    • menu
    [{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"RDD Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","year":"2020","type":"Merger","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Innovate Biopharmaceuticals \/ RDD Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Innovate Biopharmaceuticals \/ RDD Pharma"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"9 Meters Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor alpha3\/beta4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"9 Meters Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"European Biomedical Research Institute of Salerno","sponsor":"European Biomedical Research Institute of Salerno","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor alpha3\/beta4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"European Biomedical Research Institute of Salerno","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"European Biomedical Research Institute of Salerno \/ European Biomedical Research Institute of Salerno","highestDevelopmentStatusID":"6","companyTruncated":"European Biomedical Research Institute of Salerno \/ European Biomedical Research Institute of Salerno"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"9 Meters Biopharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Larazotide

    Menu

    Larazotide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Suppo...

                            Details : This study follows a Phase 2 clinical trial in 342 adult patients with celiac disease who had been on a gluten-free diet for at least 12 months, which concluded that INN-202 (larazotide) 0.5 mg significantly reduced symptoms of celiac disease.

                            Brand Name : INN-202

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 21, 2022

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            European Biomedical Research Institute of Salerno

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            European Biomedical Research Institute of Salerno

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : European Biomedical Research Institute of Salerno

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            9 Meters Biopharma Announces Agreement with EBRIS to Continue Evaluation of Larazotide for COVID-19 Respirator...

                            Details : EBRIS and 9 Meters have entered into a material transfer agreement for drug supply sufficient to initiate and complete a Phase 1 study in Australia in 2021 to assess the safety and tolerability of larazotide when delivered directly to the lungs.

                            Brand Name : AT-1001

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            December 21, 2020

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : European Biomedical Research Institute of Salerno

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            9 Meters Biopharma Announces Issuance of Patent for Use of Larazotide in Acute Lung Injury (ALI) and Acute Res...

                            Details : U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent for Use of Tight Junction Antagonists in the Treatment of Acute Lung Injury and Acute Respiratory Distress, relating to its proprietary investigational agent, larazotide.

                            Brand Name : INN-202

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            July 28, 2020

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            9 Meters Biopharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            9 Meters Biopharma, Inc. Amends Definition of Primary Endpoint for Phase 3 Trial in Celiac Disease After Consu...

                            Details : The trial is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of larazotide for patients with celiac disease who continue to experience gastrointestinal symptoms while following a gluten-free diet.

                            Brand Name : INN-202

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 29, 2020

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : RDD Pharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Innovate Biopharmaceuticals and RDD Pharma Merge to Form 9 Meters Biopharma

                            Details : Innovative to change its name to 9 Meters Biopharma. 9 Biopharma meters to focus on delivering novel approach including the first and only long-acting GLP-1 agonist receptor for Short Bowel Syndrome.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            April 30, 2020

                            Lead Product(s) : Larazotide Acetate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : RDD Pharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth